Yuanxia Liu
Founding Partner
Beijing Origintelligence Intellectual Property
Personal Profile
Liu Yuanxia has worked in the field of intellectual property for 17 years. Focusing on the protection of intellectual property in the fields of medicine, pesticides, chemistry (organic and polymer chemistry) and materials, she provides clients with legal services including patent application, patent reexamination and invalidation, administrative litigation, infringement litigation, patent validity analysis, infringement risk analysis, Freedom-to-Operate (FTO) opinions and patent portfolio.
After graduating with a Master’s degree in 2002, Liu Yuanxia worked at SIPO for 7 years. During this period, she was selected to serve as a People's Juror in No. 1 Beijing Intermediate Court due to her excellent performance. She has adjudicated nearly 120 intellectual property cases.
In 2009, she left the SIPO to join the JINCHENG TONGDA & NEAL (JT&N) and became a partner in intellectual property department. She provided all-around law services related to intellectual property for multinational and Chinese companies in the fields of medicine and chemical industry, handled nearly 60 patent infringement, invalidity, ownership and trade secret cases, and provided nearly 60 legal opinions on patent FTO, infringement analysis, effectiveness analysis, authorization prospect analysis and patentability analysis, patent strategy consulting.
Founded by Liu Yuanxia in 2014, Origintelligence provides nearly 40 project approval analysis and legal analysis for many domestic pharmaceutical intellectual property enterprises, acts as an agent for nearly 100 medicine patent invalidation infringement cases, and wins the trust of domestic well-known pharmaceutical enterprises.
【Recent Cases】
【Patent Invalidation and Judicial Proceedings】
● Represented Hengrui Medicine to successfully declare the invalidation of all the patents of Santen “Tafluprost” eye drops in 2016-2017; one of the cases was selected as 2018 Top Ten Cases of Patent Reexamination Board of SIPO
● In 2018, represented Qilu Pharmaceutical in the patent invalidation administrative case concerning the "cinepazide pharmaceutical composition", the gold award patent was revoked and valid verdict was upheld
●Represented Hengrui Medicine to successfully declare the invalidation of all the patents of “apatinib” crystal structure owned by Shanghai Xuanchuang; this case was selected as 2017 Top Ten Cases of Patent Reexamination Board of SIPO
●Represented Qilu Pharmaceutical to successfully declare the invalidation of all the patents of “cinepazide maleate” crystal structure and preparation methods owned by Sihuan Pharm in 2016-2017;
● Represented Qilu Pharmaceutical to file a lawsuit against the Patent Reexamination Board for the patent administrative case of “nitrogen oxide of cinepazide” and an invalid verdict was successfully revoked with the evidence of false experimental data.
● Represented Qilu Pharmaceutical to successfully declare the invalidation of the patents of Astellas “solifenacin” and declare the invalidation of all the patents with the evidence of inadequate disclosure in 2018
● Represented a pharmaceutical enterprise to successfully declare the invalidation of all the patents related to “ibuprofen” injection owned by Xi’an Tianyi Qinkun Pharmacy Co., Ltd. in 2016-2017
● Represented Yanzhou Tiancheng to declare the invalidation of 4 patents of Solvay “epichlorohydrin” methods, the verdict was upheld in the first trial in 2011-2014
● Represented a large Chinese pharmaceutical enterprise to declare the invalidation of some of OSI “erlotinib” crystal structure patents in 2012
● In 2012-2013, mainly participated in the “Yasmin” patent invalid administrative case sued by Bayer against the Patent Reexamination Board, invalid verdict was revoked in the first trial, the verdict was upheld in the second trial
● In 2010, participated in the case of invalidation of patents of “Nexvar” pharmaceutical compound declared by Bayer and Wang Xiurong, the invalidation verdict was upheld and the patent right was valid, the suit was won and took effect
● In 2010, participated in the case of invalidation of patents of “glyphosate” declared by Zhejiang Xin’an and Zhejiang Jinfanda, the invalidation verdict was upheld and the patent right became valid, the suit was won and took effect. In 2012, represented GSK to file a suit against the Qingdao Miuton concerning patent infringement of snoring paste and won the suit in the first trial.
● Represented Bayer to file a suit against the Nanjing Shilang concerning patent infringement of “moxifloxacin” medicine, the suit was won in the first trial and took effect. This case was awarded the 2011 Top 10 Typical Intellectual Property Cases of Jiangsu High Court in 2011
● In 2010, participated in the case sued by Hainan Coland against CTTQ concerning non-infringement of adefovir dipivoxil crystal structure patents, the case was settled in the first trial. This was the first crystal structure patent infringement case in China.
【Patent Validity Analysis/ FTO Analysis】
● Acting as an agent for a number of domestic well-known pharmaceutical enterprises to conduct patent retrieval, validity analysis, FTO analysis and public opinions on BPC, crystal structure, pharmaceutical preparations and pharmaceutical applications
● Acting as an agent for dozens of internationally renowned pharmaceutical enterprises to carry out patent validity analysis and FTO analysis on BPC, medicine, agentia, medical application and medical apparatus and instruments
● Acting as an agent for dozens of internationally renowned chemical enterprises to conduct patent retrieval, patent validity analysis, FTO analysis, infringement analysis and public opinions on chemical products, preparation methods, catalysts, regeneration technology, intermediates, etc.
【Trade Secrets/Unfair Competition】
● Represented a famous chemical enterprise to carry out trade secret analysis in 2017-2018
● Represented a chemical enterprise to file a trade secret criminal lawsuit and won the suit in 2012-2013
● Participated in the case that a famous chemical enterprise responded to the second trial of Supreme Court concerning trade secret in 2013-2014
Address: Room 1004, Block E, Kar Wah Building, No. 9, 3rd Street of Shangdi, Haidian District, Beijing Tel: +8610 6266-9046 Website: www.origintelligence.com
After graduating with a Master’s degree in 2002, Liu Yuanxia worked at SIPO for 7 years. During this period, she was selected to serve as a People's Juror in No. 1 Beijing Intermediate Court due to her excellent performance. She has adjudicated nearly 120 intellectual property cases.
In 2009, she left the SIPO to join the JINCHENG TONGDA & NEAL (JT&N) and became a partner in intellectual property department. She provided all-around law services related to intellectual property for multinational and Chinese companies in the fields of medicine and chemical industry, handled nearly 60 patent infringement, invalidity, ownership and trade secret cases, and provided nearly 60 legal opinions on patent FTO, infringement analysis, effectiveness analysis, authorization prospect analysis and patentability analysis, patent strategy consulting.
Founded by Liu Yuanxia in 2014, Origintelligence provides nearly 40 project approval analysis and legal analysis for many domestic pharmaceutical intellectual property enterprises, acts as an agent for nearly 100 medicine patent invalidation infringement cases, and wins the trust of domestic well-known pharmaceutical enterprises.
【Recent Cases】
【Patent Invalidation and Judicial Proceedings】
● Represented Hengrui Medicine to successfully declare the invalidation of all the patents of Santen “Tafluprost” eye drops in 2016-2017; one of the cases was selected as 2018 Top Ten Cases of Patent Reexamination Board of SIPO
● In 2018, represented Qilu Pharmaceutical in the patent invalidation administrative case concerning the "cinepazide pharmaceutical composition", the gold award patent was revoked and valid verdict was upheld
●Represented Hengrui Medicine to successfully declare the invalidation of all the patents of “apatinib” crystal structure owned by Shanghai Xuanchuang; this case was selected as 2017 Top Ten Cases of Patent Reexamination Board of SIPO
●Represented Qilu Pharmaceutical to successfully declare the invalidation of all the patents of “cinepazide maleate” crystal structure and preparation methods owned by Sihuan Pharm in 2016-2017;
● Represented Qilu Pharmaceutical to file a lawsuit against the Patent Reexamination Board for the patent administrative case of “nitrogen oxide of cinepazide” and an invalid verdict was successfully revoked with the evidence of false experimental data.
● Represented Qilu Pharmaceutical to successfully declare the invalidation of the patents of Astellas “solifenacin” and declare the invalidation of all the patents with the evidence of inadequate disclosure in 2018
● Represented a pharmaceutical enterprise to successfully declare the invalidation of all the patents related to “ibuprofen” injection owned by Xi’an Tianyi Qinkun Pharmacy Co., Ltd. in 2016-2017
● Represented Yanzhou Tiancheng to declare the invalidation of 4 patents of Solvay “epichlorohydrin” methods, the verdict was upheld in the first trial in 2011-2014
● Represented a large Chinese pharmaceutical enterprise to declare the invalidation of some of OSI “erlotinib” crystal structure patents in 2012
● In 2012-2013, mainly participated in the “Yasmin” patent invalid administrative case sued by Bayer against the Patent Reexamination Board, invalid verdict was revoked in the first trial, the verdict was upheld in the second trial
● In 2010, participated in the case of invalidation of patents of “Nexvar” pharmaceutical compound declared by Bayer and Wang Xiurong, the invalidation verdict was upheld and the patent right was valid, the suit was won and took effect
● In 2010, participated in the case of invalidation of patents of “glyphosate” declared by Zhejiang Xin’an and Zhejiang Jinfanda, the invalidation verdict was upheld and the patent right became valid, the suit was won and took effect. In 2012, represented GSK to file a suit against the Qingdao Miuton concerning patent infringement of snoring paste and won the suit in the first trial.
● Represented Bayer to file a suit against the Nanjing Shilang concerning patent infringement of “moxifloxacin” medicine, the suit was won in the first trial and took effect. This case was awarded the 2011 Top 10 Typical Intellectual Property Cases of Jiangsu High Court in 2011
● In 2010, participated in the case sued by Hainan Coland against CTTQ concerning non-infringement of adefovir dipivoxil crystal structure patents, the case was settled in the first trial. This was the first crystal structure patent infringement case in China.
【Patent Validity Analysis/ FTO Analysis】
● Acting as an agent for a number of domestic well-known pharmaceutical enterprises to conduct patent retrieval, validity analysis, FTO analysis and public opinions on BPC, crystal structure, pharmaceutical preparations and pharmaceutical applications
● Acting as an agent for dozens of internationally renowned pharmaceutical enterprises to carry out patent validity analysis and FTO analysis on BPC, medicine, agentia, medical application and medical apparatus and instruments
● Acting as an agent for dozens of internationally renowned chemical enterprises to conduct patent retrieval, patent validity analysis, FTO analysis, infringement analysis and public opinions on chemical products, preparation methods, catalysts, regeneration technology, intermediates, etc.
【Trade Secrets/Unfair Competition】
● Represented a famous chemical enterprise to carry out trade secret analysis in 2017-2018
● Represented a chemical enterprise to file a trade secret criminal lawsuit and won the suit in 2012-2013
● Participated in the case that a famous chemical enterprise responded to the second trial of Supreme Court concerning trade secret in 2013-2014
Address: Room 1004, Block E, Kar Wah Building, No. 9, 3rd Street of Shangdi, Haidian District, Beijing Tel: +8610 6266-9046 Website: www.origintelligence.com
